LWLimei Wan

Limei Wan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Limei Wan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Dongmei Meng

    Children’s Medical Center, The Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication
  • Jiajie Zhang

    Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism and Guangdong-Hong KongMacao Joint Laboratory for New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, China

    1 shared publication
  • Li Wei

    Department of Pharmacy, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Pengjiu Yu

    Department of Pharmacy, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.

    1 shared publication
  • Shanhe Wan

    Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism and Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China

    1 shared publication
  • Shunjun Jiang

    Department of Pharmacy The First Affiliated Hospital of Guangzhou Medical University 510120 Guangzhou China

    1 shared publication

Latest Publications

  • Open Access

    Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury

    by Limei Wan, Weibin Wu, Shunjun Jiang, Shanhe Wan, Dongmei Meng, Zhipeng Wang, Jiajie Zhang, Li Wei, Pengjiu Yu

    Recent studies have illuminated that blocking Ca2+ influx into effector cells is an attractive therapeutic strategy for lung injury. We hypothesize that T-type calcium channel may be a potential therapeutic target for acute lung injury (ALI). In this study, the pharmacological activity of mibefradil (a classical T-type calcium channel inhibitor) was assessed in a mouse model of lipopolysaccharide- (LPS-) induced ALI. In LPS challenged mice, mibefradil (20 and 40 mg/kg) dramatically decreased the total cell number, as well as the productions of TNF-α and IL-6 in bronchoalveolar lavage fluid (BALF). Mibefradil also suppressed total protein concentration in BALF, attenuated Evans blue extravasation, MPO activity, and NF-κB activation in lung tissue. Furthermore, flunarizine, a widely prescripted antimigraine agent with potent inhibition on T-type channel, was also found to protect mice against lung injury. These data demonstrated that T-type calcium channel inhibitors may be beneficial for treating acute lung injury. The important role of T-type calcium channel in the acute lung injury is encouraged to be further investigated.